&Partners’s BioXcel Therapeutics BTAI Stock Holding History

&Partners’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Buy	83,588 +2,724	+3%	+$3.19K	﹤0.01%	2448
2026 Q1	$108K	Buy	+80,864	New	+$133K	﹤0.01%	2334

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

&Partners's BTAI Position: Q2 2026 in Review

&Partners increased its BioXcel Therapeutics (BTAI) stake by 3.4% in Q2 2026, buying an estimated $3.19K and bringing the position to 83,588 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

&Partners first reported a position in BTAI in Q1 2026 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

&Partners held 83,588 shares of BioXcel Therapeutics worth $118K as of Q2 2026.
&Partners bought 2,724 BioXcel Therapeutics shares in Q2 2026, an estimated $3.19K.
BioXcel Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2448 holding.
&Partners first reported a position in BioXcel Therapeutics in Q1 2026 and has held it in 2 quarters since.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.